Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.70
NYSE:JNJ's Cash to Debt is ranked higher than
66% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. NYSE:JNJ: 1.70 )
NYSE:JNJ' s 10-Year Cash to Debt Range
Min: 0.17   Max: 6.28
Current: 1.7

0.17
6.28
Equity to Asset 0.57
NYSE:JNJ's Equity to Asset is ranked higher than
64% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. NYSE:JNJ: 0.57 )
NYSE:JNJ' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.67
Current: 0.57

0.46
0.67
Interest Coverage 38.13
NYSE:JNJ's Interest Coverage is ranked higher than
62% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. NYSE:JNJ: 38.13 )
NYSE:JNJ' s 10-Year Interest Coverage Range
Min: 23.47   Max: 230.91
Current: 38.13

23.47
230.91
F-Score: 7
Z-Score: 5.25
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 25.77
NYSE:JNJ's Operating margin (%) is ranked higher than
94% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. NYSE:JNJ: 25.77 )
NYSE:JNJ' s 10-Year Operating margin (%) Range
Min: 18.63   Max: 26.92
Current: 25.77

18.63
26.92
Net-margin (%) 19.40
NYSE:JNJ's Net-margin (%) is ranked higher than
92% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. NYSE:JNJ: 19.40 )
NYSE:JNJ' s 10-Year Net-margin (%) Range
Min: 12.52   Max: 21.65
Current: 19.4

12.52
21.65
ROE (%) 18.68
NYSE:JNJ's ROE (%) is ranked higher than
93% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NYSE:JNJ: 18.68 )
NYSE:JNJ' s 10-Year ROE (%) Range
Min: 16.74   Max: 30.46
Current: 18.68

16.74
30.46
ROA (%) 10.42
NYSE:JNJ's ROA (%) is ranked higher than
93% of the 748 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. NYSE:JNJ: 10.42 )
NYSE:JNJ' s 10-Year ROA (%) Range
Min: 8.51   Max: 17.09
Current: 10.42

8.51
17.09
ROC (Joel Greenblatt) (%) 79.60
NYSE:JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. NYSE:JNJ: 79.60 )
NYSE:JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 44.64   Max: 109.92
Current: 79.6

44.64
109.92
Revenue Growth (%) 3.90
NYSE:JNJ's Revenue Growth (%) is ranked higher than
66% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NYSE:JNJ: 3.90 )
NYSE:JNJ' s 10-Year Revenue Growth (%) Range
Min: 1.4   Max: 14.8
Current: 3.9

1.4
14.8
EBITDA Growth (%) -1.50
NYSE:JNJ's EBITDA Growth (%) is ranked higher than
64% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. NYSE:JNJ: -1.50 )
NYSE:JNJ' s 10-Year EBITDA Growth (%) Range
Min: -6.6   Max: 16.5
Current: -1.5

-6.6
16.5
EPS Growth (%) 0.20
NYSE:JNJ's EPS Growth (%) is ranked higher than
69% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NYSE:JNJ: 0.20 )
NYSE:JNJ' s 10-Year EPS Growth (%) Range
Min: -8.6   Max: 20.2
Current: 0.2

-8.6
20.2
» NYSE:JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

JNJ Guru Trades in Q3 2013

Joel Greenblatt 32,599 sh (New)
Ray Dalio 27,293 sh (New)
Louis Moore Bacon 5,694 sh (New)
Richard Pzena 847,758 sh (+8050.74%)
Steven Cohen 151,123 sh (+611.8%)
Ruane Cunniff 74,495 sh (+420.69%)
Jim Simons 3,275,300 sh (+350.27%)
Paul Tudor Jones 7,100 sh (+195.83%)
Sarah Ketterer 426,250 sh (+45.3%)
John Rogers 127,576 sh (+33.75%)
Robert Olstein 92,000 sh (+2.22%)
Murray Stahl 31,214 sh (+1.34%)
Jean-Marie Eveillard 1,596,580 sh (+1.27%)
Mario Gabelli 409,421 sh (+0.82%)
James Barrow 17,194,257 sh (+0.22%)
Richard Snow 3,235 sh (+0.15%)
Stanley Druckenmiller 129,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Michael Price 35,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Dodge & Cox 38,725 sh (unchged)
Richard Perry 388,897 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Jeff Auxier 97,577 sh (unchged)
Ken Fisher 10,143,775 sh (-0.17%)
Tweedy Browne 4,324,131 sh (-0.35%)
Tom Gayner 580,800 sh (-0.37%)
Bill Frels 1,815,415 sh (-0.99%)
Mark Hillman 30,829 sh (-1.02%)
PRIMECAP Management 13,813,887 sh (-1.3%)
Donald Yacktman 9,619,720 sh (-1.44%)
HOTCHKIS & WILEY 4,134,878 sh (-3.27%)
Manning & Napier Advisors, Inc 4,152,996 sh (-6.99%)
Jeremy Grantham 21,210,245 sh (-8.46%)
Pioneer Investments 3,879,715 sh (-8.53%)
Vanguard Health Care Fund 2,897,600 sh (-11.42%)
First Pacific Advisors 1,498,300 sh (-17.82%)
Steven Romick 1,425,000 sh (-17.87%)
John Hussman 202,650 sh (-19.79%)
Chris Davis 163,492 sh (-21.51%)
George Soros 1,267,000 sh (-50%)
Prem Watsa 2,941,741 sh (-50.27%)
Chuck Royce 13,500 sh (-66.42%)
» More
Q4 2013

JNJ Guru Trades in Q4 2013

Ray Dalio 113,193 sh (+314.73%)
Paul Tudor Jones 26,088 sh (+267.44%)
John Rogers 349,157 sh (+173.69%)
Stanley Druckenmiller 235,000 sh (+82.17%)
Jim Simons 5,498,400 sh (+67.87%)
Steven Cohen 224,813 sh (+48.76%)
Sarah Ketterer 559,450 sh (+31.25%)
Murray Stahl 32,614 sh (+4.49%)
Pioneer Investments 4,013,743 sh (+3.45%)
Richard Pzena 866,458 sh (+2.21%)
James Barrow 17,330,009 sh (+0.79%)
Chris Davis 164,755 sh (+0.77%)
Jean-Marie Eveillard 1,607,280 sh (+0.67%)
Mario Gabelli 411,797 sh (+0.58%)
Bill Frels 1,821,701 sh (+0.35%)
First Pacific Advisors 1,501,800 sh (+0.23%)
Ken Fisher 10,165,567 sh (+0.21%)
Richard Snow 3,235 sh (unchged)
Michael Price 35,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Steven Romick 1,425,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Tom Gayner 580,600 sh (-0.03%)
Donald Yacktman 9,610,642 sh (-0.09%)
Jeff Auxier 97,452 sh (-0.13%)
Dodge & Cox 38,625 sh (-0.26%)
Mark Hillman 30,746 sh (-0.27%)
Tweedy Browne 4,305,931 sh (-0.42%)
Manning & Napier Advisors, Inc 4,132,692 sh (-0.49%)
Ruane Cunniff 74,094 sh (-0.54%)
PRIMECAP Management 13,689,047 sh (-0.9%)
Robert Olstein 91,000 sh (-1.09%)
Jeremy Grantham 19,775,624 sh (-6.76%)
HOTCHKIS & WILEY 3,819,961 sh (-7.62%)
Richard Perry 342,277 sh (-11.99%)
Chuck Royce 11,300 sh (-16.3%)
John Hussman 102,650 sh (-49.35%)
Prem Watsa 84,700 sh (-97.12%)
» More
Q1 2014

JNJ Guru Trades in Q1 2014

RS Investment Management 7,228 sh (New)
Joel Greenblatt 7,496 sh (New)
George Soros 102,500 sh (New)
John Buckingham 45,697 sh (New)
Ray Dalio 262,993 sh (+132.34%)
First Pacific Advisors 1,936,200 sh (+28.93%)
Steven Romick 1,835,000 sh (+28.77%)
Sarah Ketterer 696,350 sh (+24.47%)
Robert Olstein 110,000 sh (+20.88%)
Manning & Napier Advisors, Inc 4,727,195 sh (+14.39%)
Bill Frels 2,011,442 sh (+10.42%)
John Rogers 366,918 sh (+5.09%)
HOTCHKIS & WILEY 3,932,985 sh (+2.96%)
Ruane Cunniff 75,794 sh (+2.29%)
Jean-Marie Eveillard 1,617,567 sh (+0.64%)
Richard Snow 3,245 sh (+0.31%)
Richard Pzena 868,139 sh (+0.19%)
Yacktman Fund 4,050,000 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Michael Price 35,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Perry 342,277 sh (unchged)
Dodge & Cox 38,625 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Chris Davis Sold Out
Stanley Druckenmiller Sold Out
Jeff Auxier 97,237 sh (-0.22%)
Donald Yacktman 9,572,850 sh (-0.39%)
Tweedy Browne 4,269,206 sh (-0.85%)
Murray Stahl 32,329 sh (-0.87%)
Tom Gayner 574,200 sh (-1.1%)
Ken Fisher 9,977,824 sh (-1.85%)
James Barrow 16,953,029 sh (-2.18%)
Pioneer Investments 3,891,373 sh (-3.05%)
Mario Gabelli 395,061 sh (-4.06%)
PRIMECAP Management 12,300,986 sh (-10.14%)
Jeremy Grantham 17,574,048 sh (-11.13%)
Chuck Royce 7,300 sh (-35.4%)
Jim Simons 2,659,200 sh (-51.64%)
Paul Tudor Jones 4,000 sh (-84.67%)
Steven Cohen 9,821 sh (-95.63%)
John Hussman 2,650 sh (-97.42%)
» More
Q2 2014

JNJ Guru Trades in Q2 2014

Ken Fisher 10,448,448 sh (+4.72%)
Manning & Napier Advisors, Inc 4,769,286 sh (+0.89%)
Yacktman Fund 4,050,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Steven Romick 1,750,000 sh (-4.63%)
Yacktman Focused Fund 3,300,000 sh (-13.16%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Yacktman Focused Fund 2014-06-30 Reduce -13.16%0.51%$96.54 - $105.76 $ 100.09-1%3300000
John Hussman 2014-03-31 Reduce -97.42%0.65%$86.62 - $97.44 $ 100.098%2650
PRIMECAP Management 2014-03-31 Reduce -10.14%0.15%$86.62 - $97.44 $ 100.098%12300986
Ray Dalio 2014-03-31 Add 132.34%0.12%$86.62 - $97.44 $ 100.098%262993
George Soros 2014-03-31 New Buy0.1%$86.62 - $97.44 $ 100.098%102500
Joel Greenblatt 2014-03-31 New Buy0.01%$86.62 - $97.44 $ 100.098%7496
Prem Watsa 2013-12-31 Reduce -97.12%15.54%$85.61 - $95.63 $ 100.098%84700
George Soros 2013-12-31 Sold Out 1.2%$85.61 - $95.63 $ 100.098%0
Vanguard Health Care Fund 2013-12-31 Sold Out 0.85%$85.61 - $95.63 $ 100.098%0
John Hussman 2013-12-31 Reduce -49.35%0.48%$85.61 - $95.63 $ 100.098%102650
Joel Greenblatt 2013-12-31 Sold Out 0.09%$85.61 - $95.63 $ 100.098%0
Ray Dalio 2013-12-31 Add 314.73%0.06%$85.61 - $95.63 $ 100.098%113193
Prem Watsa 2013-09-30 Reduce -50.27%10.26%$86.17 - $94.39 $ 100.0911%2941741
George Soros 2013-09-30 Reduce -50%1.2%$86.17 - $94.39 $ 100.0911%1267000
John Hussman 2013-09-30 Reduce -19.79%0.2%$86.17 - $94.39 $ 100.0911%202650
Vanguard Health Care Fund 2013-09-30 Reduce -11.42%0.11%$86.17 - $94.39 $ 100.0911%2897600
Joel Greenblatt 2013-09-30 New Buy0.09%$86.17 - $94.39 $ 100.0911%32599
Ruane Cunniff 2013-09-30 Add 420.69%0.03%$86.17 - $94.39 $ 100.0911%74495
Ray Dalio 2013-09-30 New Buy0.02%$86.17 - $94.39 $ 100.0911%27293
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.00
NYSE:JNJ's P/E(ttm) is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. NYSE:JNJ: 19.00 )
NYSE:JNJ' s 10-Year P/E(ttm) Range
Min: 10.5   Max: 24.45
Current: 19

10.5
24.45
P/B 3.80
NYSE:JNJ's P/B is ranked higher than
65% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. NYSE:JNJ: 3.80 )
NYSE:JNJ' s 10-Year P/B Range
Min: 2.68   Max: 6.21
Current: 3.8

2.68
6.21
P/S 4.01
NYSE:JNJ's P/S is ranked higher than
66% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. NYSE:JNJ: 4.01 )
NYSE:JNJ' s 10-Year P/S Range
Min: 2.16   Max: 4.28
Current: 4.01

2.16
4.28
PFCF 18.60
NYSE:JNJ's PFCF is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:JNJ: 18.60 )
NYSE:JNJ' s 10-Year PFCF Range
Min: 10.29   Max: 24.69
Current: 18.6

10.29
24.69
EV-to-EBIT 14.44
NYSE:JNJ's EV-to-EBIT is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. NYSE:JNJ: 14.44 )
NYSE:JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 18.7
Current: 14.44

8.4
18.7
PEG 9.30
NYSE:JNJ's PEG is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 367.50 vs. NYSE:JNJ: 9.30 )
NYSE:JNJ' s 10-Year PEG Range
Min: 1.18   Max: 246
Current: 9.3

1.18
246
Shiller P/E 21.50
NYSE:JNJ's Shiller P/E is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:JNJ: 21.50 )
NYSE:JNJ' s 10-Year Shiller P/E Range
Min: 13.04   Max: 31.12
Current: 21.5

13.04
31.12
Current Ratio 2.41
NYSE:JNJ's Current Ratio is ranked higher than
70% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. NYSE:JNJ: 2.41 )
NYSE:JNJ' s 10-Year Current Ratio Range
Min: 1.2   Max: 2.69
Current: 2.41

1.2
2.69
Quick Ratio 2.07
NYSE:JNJ's Quick Ratio is ranked higher than
74% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. NYSE:JNJ: 2.07 )
NYSE:JNJ' s 10-Year Quick Ratio Range
Min: 0.94   Max: 2.37
Current: 2.07

0.94
2.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.68
NYSE:JNJ's Dividend Yield is ranked higher than
79% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. NYSE:JNJ: 2.68 )
NYSE:JNJ' s 10-Year Dividend Yield Range
Min: 1.64   Max: 3.84
Current: 2.68

1.64
3.84
Dividend Payout 0.51
NYSE:JNJ's Dividend Payout is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:JNJ: 0.51 )
NYSE:JNJ' s 10-Year Dividend Payout Range
Min: 0.29   Max: 13.89
Current: 0.51

0.29
13.89
Dividend growth (3y) 7.10
NYSE:JNJ's Dividend growth (3y) is ranked higher than
82% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. NYSE:JNJ: 7.10 )
NYSE:JNJ' s 10-Year Dividend growth (3y) Range
Min: 7.1   Max: 17.1
Current: 7.1

7.1
17.1
Yield on cost (5-Year) 3.72
NYSE:JNJ's Yield on cost (5-Year) is ranked higher than
87% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. NYSE:JNJ: 3.72 )
NYSE:JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 2.34   Max: 5.49
Current: 3.72

2.34
5.49
Share Buyback Rate -1.00
NYSE:JNJ's Share Buyback Rate is ranked higher than
75% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.70 vs. NYSE:JNJ: -1.00 )
NYSE:JNJ' s 10-Year Share Buyback Rate Range
Min: 2   Max: -4.9
Current: -1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.60
NYSE:JNJ's Price/Tangible Book is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NYSE:JNJ: 10.60 )
NYSE:JNJ' s 10-Year Price/Tangible Book Range
Min: 6.25   Max: 20.45
Current: 10.6

6.25
20.45
Price/DCF (Projected) 1.60
NYSE:JNJ's Price/DCF (Projected) is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:JNJ: 1.60 )
NYSE:JNJ' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 3.6
Current: 1.6

0.84
3.6
Price/Median PS Value 1.20
NYSE:JNJ's Price/Median PS Value is ranked higher than
66% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. NYSE:JNJ: 1.20 )
NYSE:JNJ' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 1.88
Current: 1.2

0.69
1.88
Price/Graham Number 3.00
NYSE:JNJ's Price/Graham Number is ranked higher than
74% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. NYSE:JNJ: 3.00 )
NYSE:JNJ' s 10-Year Price/Graham Number Range
Min: 1.95   Max: 6.12
Current: 3

1.95
6.12
Earnings Yield (Greenblatt) 7.00
NYSE:JNJ's Earnings Yield (Greenblatt) is ranked higher than
81% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. NYSE:JNJ: 7.00 )
NYSE:JNJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.3   Max: 11.9
Current: 7

5.3
11.9
Forward Rate of Return (Yacktman) 1.93
NYSE:JNJ's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. NYSE:JNJ: 1.93 )
NYSE:JNJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 18.2
Current: 1.93

1
18.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJ.Germany
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients. RISPERDAL CONSTA, a long-acting injectable, and INVEGATM Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN and FLOXIN, both in the anti-infective field; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used mainly in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. In a

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Gurufocus
ReplyGurufocus - 9 months ago
test

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide